FIELD: medicine.
SUBSTANCE: method for prediction of recurrent cervical cancer involves biochemical daily urine analysis to determine daily urine androsterone and etiocholanolone to be related; if the relation is 0.75 mg/day or less, the recurrent disease is predicted for the first 2 years, and if the relation exceeding 0.75 mg/day, a prolonged recurrence-free period up to 10 years or more is predicted.
EFFECT: method enables the early, preclinical detection of the recurrent disease, as well as an individual selection of therapeutic approaches to each patient.
2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR MALIGNANT TUMOUR DISEASE RECURRENCE PREDICTION | 2015 |
|
RU2620306C2 |
| METHOD FOR PREDICTION OF HIGH RISK OF RECURRENCE IN PATIENTS WITH IB STAGE OF CERVICAL CANCER WHO RECEIVED COMBINED TREATMENT | 2020 |
|
RU2732769C1 |
| METHOD FOR PREDICTION OF CERVICAL CANCER METASTASES | 2010 |
|
RU2436102C1 |
| METHOD FOR PREDICTION OF RECURRENCES OF POSTOPERATIVE MENINGIOMAS | 2018 |
|
RU2689795C1 |
| METHOD FOR PREDICTION OF RECURRENT VULVAR CANCER | 2013 |
|
RU2517541C1 |
| METHOD OF FORECASTING RETROCESSIONS OF LARYNX CANCER | 2008 |
|
RU2389030C1 |
| METHOD OF DETERMINING EFFICIENCY OF TREATMENT OF UTERINE BODY CANCER | 2010 |
|
RU2424806C1 |
| METHOD FOR PREDICTION OF BREAST CANCER DISSEMINATION IN PREMENOPAUSAL FEMALES | 2011 |
|
RU2463599C1 |
| METHOD FOR PREDICTING THE DURATION OF RELAPSE-FREE PERIOD IN PATIENTS WITH MAMMARY CANCER | 2003 |
|
RU2251692C2 |
| METHOD FOR PREDICTING RECURRENT DISEASE | 2010 |
|
RU2471191C2 |
